{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:52:29Z","timestamp":1788587549507,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ningbo Top Medical and Health Research Program","award":["No.2022020203"],"award-info":[{"award-number":["No.2022020203"]}]},{"name":"2025 Key Research and Development Plan","award":["2023Z162-Jiang JH"],"award-info":[{"award-number":["2023Z162-Jiang JH"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-33144-x","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:45:34Z","timestamp":1767023134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of prostate cancer by urinary DLX1\/HOXC6 expression in Chinese population with prostate-specific antigen levels of 4\u201310\u00a0ng\/mL"],"prefix":"10.1038","volume":"16","author":[{"given":"Dongxu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"33144_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22037\/uj.v20i.7687","volume":"21","author":"M Amiri","year":"2024","unstructured":"Amiri, M. et al. New molecular markers for prostate cancer diagnosis. Urol. J. 21, 1\u201313. https:\/\/doi.org\/10.22037\/uj.v20i.7687 (2024).","journal-title":"Urol. J."},{"key":"33144_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86, 148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027 (2024).","journal-title":"Eur. Urol."},{"key":"33144_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.eururo.2015.11.010","volume":"70","author":"CJD Wallis","year":"2016","unstructured":"Wallis, C. J. D. et al. Surgery versus radiotherapy for clinically-localized prostate cancer: A systematic review and meta-analysis. Eur. Urol. 70, 21\u201330. https:\/\/doi.org\/10.1016\/j.eururo.2015.11.010 (2016).","journal-title":"Eur. Urol."},{"key":"33144_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000519861","volume":"100","author":"V Achard","year":"2022","unstructured":"Achard, V., Putora, P. M., Omlin, A., Zilli, T. & Fischer, S. Metastatic prostate cancer: Treatment options. Oncology 100, 48\u201359. https:\/\/doi.org\/10.1159\/000519861 (2022).","journal-title":"Oncology"},{"key":"33144_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki, D. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: Treatment of relapsing and metastatic prostate cancer. Eur. Urol. 86, 164\u2013182. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010 (2024).","journal-title":"Eur. Urol."},{"key":"33144_CR6","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.5152\/tud.2020.20358","volume":"47","author":"G Ortner","year":"2021","unstructured":"Ortner, G., Tzanaki, E., Rai, B. P., Nagele, U. & Tokas, T. Transperineal prostate biopsy: The modern gold standard to prostate cancer diagnosis. Turk. J. Urol. 47, S19\u2013S26. https:\/\/doi.org\/10.5152\/tud.2020.20358 (2021).","journal-title":"Turk. J. Urol."},{"key":"33144_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2298\/aci0504023r","volume":"52","author":"I Romics","year":"2005","unstructured":"Romics, I. Ultrasound guided biopsy, a gold standard diagnostical test of the prostate cancer. Acta Chir. Iugosl. 52, 23\u201326. https:\/\/doi.org\/10.2298\/aci0504023r (2005).","journal-title":"Acta Chir. Iugosl."},{"key":"33144_CR8","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1017\/S0950268815002885","volume":"144","author":"HY Bennett","year":"2016","unstructured":"Bennett, H. Y., Roberts, M. J., Doi, S. A. & Gardiner, R. A. The global burden of major infectious complications following prostate biopsy. Epidemiol. Infect. 144, 1784\u20131791. https:\/\/doi.org\/10.1017\/S0950268815002885 (2016).","journal-title":"Epidemiol. Infect."},{"key":"33144_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.juro.2016.11.081","volume":"197","author":"JA Halpern","year":"2017","unstructured":"Halpern, J. A. et al. Indications, utilization and complications following prostate biopsy: New York state analysis. J. Urol. 197, 1020\u20131025. https:\/\/doi.org\/10.1016\/j.juro.2016.11.081 (2017).","journal-title":"J. Urol."},{"key":"33144_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","volume":"64","author":"S Loeb","year":"2013","unstructured":"Loeb, S. et al. Systematic review of complications of prostate biopsy. Eur. Urol. 64, 876\u2013892. https:\/\/doi.org\/10.1016\/j.eururo.2013.05.049 (2013).","journal-title":"Eur. Urol."},{"key":"33144_CR11","first-page":"5875","volume":"18","author":"LG Gomella","year":"2011","unstructured":"Gomella, L. G. et al. Screening for prostate cancer: The current evidence and guidelines controversy. Can. J. Urol. 18, 5875\u20135883 (2011).","journal-title":"Can. J. Urol."},{"key":"33144_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","volume":"19","author":"H Van Poppel","year":"2022","unstructured":"Van Poppel, H. et al. Serum PSA-based early detection of prostate cancer in Europe and globally: Past, present and future. Nat. Rev. Urol. 19, 562\u2013572. https:\/\/doi.org\/10.1038\/s41585-022-00638-6 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"33144_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.eururo.2005.04.015","volume":"48","author":"AW Roddam","year":"2005","unstructured":"Roddam, A. W. et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2\u201310 ng\/ml: Systematic review and meta-analysis. Eur. Urol. 48, 386\u2013399. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.015 (2005).","journal-title":"Eur. Urol."},{"key":"33144_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/iju.13734","volume":"25","author":"K Fujita","year":"2018","unstructured":"Fujita, K. & Nonomura, N. Urinary biomarkers of prostate cancer. Int. J. Urol. 25, 770\u2013779. https:\/\/doi.org\/10.1111\/iju.13734 (2018).","journal-title":"Int. J. Urol."},{"key":"33144_CR15","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","volume":"2","author":"J McKiernan","year":"2016","unstructured":"McKiernan, J. et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2, 882\u2013889. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0097 (2016).","journal-title":"JAMA Oncol."},{"key":"33144_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41391-022-00562-1","volume":"25","author":"WCH Visser","year":"2022","unstructured":"Visser, W. C. H. et al. Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer. Prostate Cancer Prostat. Dis. 25, 583\u2013589. https:\/\/doi.org\/10.1038\/s41391-022-00562-1 (2022).","journal-title":"Prostate Cancer Prostat. Dis."},{"key":"33144_CR17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41391-021-00367-8","volume":"24","author":"RJ Hendriks","year":"2021","unstructured":"Hendriks, R. J. et al. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: A prospective, multicenter study in biopsy-naive men. Prostate Cancer Prostat. Dis. 24, 1110\u20131119. https:\/\/doi.org\/10.1038\/s41391-021-00367-8 (2021).","journal-title":"Prostate Cancer Prostat. Dis."},{"key":"33144_CR18","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/pros.23065","volume":"75","author":"AR Hamid","year":"2015","unstructured":"Hamid, A. R. et al. The role of HOXC6 in prostate cancer development. Prostate 75, 1868\u20131876. https:\/\/doi.org\/10.1002\/pros.23065 (2015).","journal-title":"Prostate"},{"key":"33144_CR19","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1080\/21691401.2019.1635136","volume":"47","author":"J Zhou","year":"2019","unstructured":"Zhou, J., Yang, X., Song, P., Wang, H. & Wang, X. HOXC6 in the prognosis of prostate cancer. Artif. Cells Nanomed. Biotechnol. 47, 2715\u20132720. https:\/\/doi.org\/10.1080\/21691401.2019.1635136 (2019).","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"33144_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.yexcr.2018.01.007","volume":"363","author":"M Liang","year":"2018","unstructured":"Liang, M. et al. DLX1, a binding protein of beta-catenin, promoted the growth and migration of prostate cancer cells. Exp. Cell Res. 363, 26\u201332. https:\/\/doi.org\/10.1016\/j.yexcr.2018.01.007 (2018).","journal-title":"Exp. Cell Res."},{"key":"33144_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/and.14230","volume":"53","author":"Q Li","year":"2021","unstructured":"Li, Q., Xu, K., Tian, J., Lu, Z. & Pu, J. MiR-129-5p\/DLX1 signalling axis mediates functions of prostate cancer during malignant progression. Andrologia 53, e14230. https:\/\/doi.org\/10.1111\/and.14230 (2021).","journal-title":"Andrologia"},{"key":"33144_CR22","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1111\/jcmm.14402","volume":"23","author":"B Sun","year":"2019","unstructured":"Sun, B., Fan, Y., Yang, A., Liang, L. & Cao, J. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-beta\/Smad4 signalling pathway by down-regulating DLX1. J. Cell. Mol. Med. 23, 5934\u20135948. https:\/\/doi.org\/10.1111\/jcmm.14402 (2019).","journal-title":"J. Cell. Mol. Med."},{"key":"33144_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","volume":"70","author":"L Van Neste","year":"2016","unstructured":"Van Neste, L. et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur. Urol. 70, 740\u2013748. https:\/\/doi.org\/10.1016\/j.eururo.2016.04.012 (2016).","journal-title":"Eur. Urol."},{"key":"33144_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41391-022-00538-1","volume":"25","author":"R Sari Motlagh","year":"2022","unstructured":"Sari Motlagh, R. et al. Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. Prostate Cancer Prostat. Dis. 25, 187\u2013198. https:\/\/doi.org\/10.1038\/s41391-022-00538-1 (2022).","journal-title":"Prostate Cancer Prostat. Dis."},{"key":"33144_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285745","volume":"19","author":"H Wu","year":"2024","unstructured":"Wu, H. et al. A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer. PLoS ONE 19, e0285745. https:\/\/doi.org\/10.1371\/journal.pone.0285745 (2024).","journal-title":"PLoS ONE"},{"key":"33144_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41391-021-00456-8","volume":"25","author":"E Margolis","year":"2022","unstructured":"Margolis, E. et al. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer Prostat. Dis. 25, 296\u2013301. https:\/\/doi.org\/10.1038\/s41391-021-00456-8 (2022).","journal-title":"Prostate Cancer Prostat. Dis."},{"key":"33144_CR27","doi-asserted-by":"publisher","first-page":"1686991","DOI":"10.1155\/2022\/1686991","volume":"2022","author":"B Opoku Mensah","year":"2022","unstructured":"Opoku Mensah, B., Fondjo, L. A., Owiredu, W. & Adusei, B. Urinary PCA3 a superior diagnostic biomarker for prostate cancer among Ghanaian men. Dis. Markers 2022, 1686991. https:\/\/doi.org\/10.1155\/2022\/1686991 (2022).","journal-title":"Dis. Markers"},{"key":"33144_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1590\/S1677-5538.IBJU.2019.0360","volume":"46","author":"Z Qin","year":"2020","unstructured":"Qin, Z. et al. Diagnosis accuracy of PCA3 level in patients with prostate cancer: A systematic review with meta-analysis. Int. Braz. J. Urol. 46, 691\u2013704. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2019.0360 (2020).","journal-title":"Int. Braz. J. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33144-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33144-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33144-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:47:57Z","timestamp":1769431677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33144-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33144"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33144-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.X. and J.W. are employees of Hangzhou York Biotech Co., Ltd., The patents related to this work have been submitted. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This prospective study was approved by the Institutional ethic committee of The First Hospital of Zhejiang University School of Medicine (Approval number \u6d59\u5927\u4e00\u9662\u4f26\u5ba12023\u7814\u7b2c0771\u53f7-\u5feb).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"3293"}}